Table 6. List of population representation assessment results for COVID-19 trial NCT04540406.
| Trait | Initial Assessment g_l = 0.001, #p_l < 20 |
1st relaxation:
remove “have prediabetes or T2DM”
g_l = 0.82, # p_l = 9,013 |
2nd relaxation:
remove “No Extracorporeal membrane oxygenation”
g_l =0.82, # p_l =9,013 |
|||
|---|---|---|---|---|---|---|
| g_t | #p_t | g_t | #p_t | g_t | #p_t | |
| Age >= 18 | 0.94 | 9,057 | 0.94 | 9,057 | 0.94 | 9,057 |
| Sex: all | 1.00 | 9,664 | 1.00 | 9,664 | 1.00 | 9,664 |
| Disease caused by severe acute respiratory syndrome coronavirus 2 | 1.00 | 9,664 | 1.00 | 9,664 | 1.00 | 9,664 |
| No Blood transfusion reaction | 0.99 | 9,654 | 0.99 | 9,654 | 0.99 | 9,654 |
| No Extracorporeal membrane oxygenation | 0.98 | 9,621 | 0.98 | 9,621 | ||
| Have prediabetes or T2DM | 0.002 | < 20 | ||||
Abbreviations: COVID-19, novel coronavirus disease 2019. T2DM, type 2 diabetes mellitus.
Note: # p_t : the number of eligible patients for a specific trait, # p_l : the number of eligible patients for all traits. “Relaxed” traits are in italics. To protect patient privacy, all criteria where the count of eligible patients less than 100 were not provided with the actual number.